VBLT News and Press, Vascular Biogenics Ltd. From 02/26/23

NEW YORK, NY / ACCESSWIRE / February 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Jounce Therapeutics, Inc. (NAS...

3 Tips for Making Money With Penny Stocks When Day Trading When it comes to day trading, many traders look to penny stocks as a way to maximize their returns. Penny stocks are low-priced stocks that trade for less than $5 per share, and they are often associated with high risk and high re...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Vascular Biogenics (NASDAQ: VBLT ) stock is rocketing higher on Thursday following news of a merger with Notable Labs . The details of the deal include shareholders of Notable Labs rece...

Penny Stock News Sent These Stocks Higher On Thursday If you’re looking for the top penny stocks to buy, chances are you’re looking for a catalyst. Whether its broader stock market headlines or company-specific news, press releases are typically the first place to look. As w...

Israel-based biotech Vascular Biogenics ( NASDAQ: VBLT ), operating as VBL Therapeutics, added ~85% after the company and U.S. privately-held firm Notable Labs, Inc. announced a merger agreement to combine in an all-stock transaction. Per the terms, Notable stockholders are expect...

Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) Notable’s validated PPMP combines mu...

MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today that it has entered into an agreement to monetize its manufacturing facility in Modiin, Israel an...

VBL Therapeutics press release ( NASDAQ: VBLT ): Q3 GAAP EPS of -$0.12 in-line. Revenue of $0.5M (+150.0% Y/Y) beats by $0.3M . At September 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $27.7M. VBL expects t...

TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and prov...

VBL Therapeutics ( NASDAQ: VBLT ) said it had received a written notification from the Nasdaq Stock Market, notifying the company that it is not in compliance with the minimum bid price requirement. The company said the closing bid price of the VBL’s ordinary shares...